Pharma Strategy

Novo Nordisk closed its internal cell therapy unit and licensed the program to AI-driven Cellular Intelligence instead of building it in-house, with shares up nearly 25% over 30 days. The move tracks a broader pharma shift toward licensing AI biology platforms rather than owning R&D outright, as firms like MindWalk, NVIDIA BioNeMo, Owkin and Boltz Lab compete to control the underlying data layer of drug discovery.

Novo Nordisk is closing its internal cell therapy program and licensing a Parkinson's asset to an AI-driven discovery platform, even as its stock climbs 24.9% over 30 days. The move reflects a broader pivot: pharma incumbents are reallocating R&D capital toward AI foundation-model platforms like NVIDIA BioNeMo and MindWalk's HYFT rather than building discovery capability internally.

Novo Nordisk's stock gained 24.9% over 30 days after the company exited internal cell therapy and licensed its program to AI partner Cellular Intelligence, which secured FDA Fast Track designation for a Parkinson's therapy. NVIDIA's BioNeMo platform is simultaneously embedding GPU-accelerated drug discovery into Thermo Fisher and Eli Lilly pipelines. The moves signal that AI-enabled external licensing is displacing internal R&D as the preferred pharma capital allocation strategy.